Name | Number of supported studies | Average coverage | |
---|---|---|---|
platelet | 8 studies | 50% ± 21% | |
endothelial cell | 5 studies | 24% ± 9% | |
macrophage | 5 studies | 20% ± 3% | |
megakaryocyte | 4 studies | 33% ± 15% | |
plasmacytoid dendritic cell | 4 studies | 19% ± 2% | |
non-classical monocyte | 3 studies | 40% ± 17% | |
erythrocyte | 3 studies | 21% ± 2% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 1872.46 | 226 / 226 | 100% | 54.96 | 406 / 406 |
uterus | 100% | 1848.72 | 170 / 170 | 100% | 37.75 | 459 / 459 |
kidney | 100% | 1913.11 | 89 / 89 | 100% | 50.60 | 900 / 901 |
thymus | 100% | 3261.71 | 653 / 653 | 100% | 69.70 | 604 / 605 |
brain | 100% | 3572.81 | 2634 / 2642 | 100% | 79.69 | 705 / 705 |
lung | 100% | 2668.10 | 577 / 578 | 100% | 44.28 | 1153 / 1155 |
breast | 100% | 3030.79 | 459 / 459 | 100% | 56.33 | 1114 / 1118 |
bladder | 100% | 2952.76 | 21 / 21 | 99% | 37.87 | 501 / 504 |
prostate | 100% | 2647.27 | 244 / 245 | 100% | 55.58 | 501 / 502 |
esophagus | 100% | 3486.74 | 1444 / 1445 | 99% | 26.82 | 182 / 183 |
intestine | 100% | 3721.67 | 965 / 966 | 99% | 30.68 | 521 / 527 |
adrenal gland | 100% | 1901.66 | 257 / 258 | 99% | 43.91 | 228 / 230 |
stomach | 99% | 1616.16 | 356 / 359 | 99% | 30.68 | 282 / 286 |
skin | 97% | 1512.27 | 1759 / 1809 | 100% | 53.91 | 472 / 472 |
ovary | 86% | 860.31 | 155 / 180 | 100% | 44.91 | 430 / 430 |
pancreas | 64% | 522.58 | 209 / 328 | 100% | 46.84 | 178 / 178 |
adipose | 100% | 3636.87 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 40.04 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 54.15 | 29 / 29 |
muscle | 100% | 2923.84 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3171.32 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 41.99 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 28.86 | 1 / 1 |
heart | 100% | 3435.44 | 860 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3066.39 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 96% | 4701.72 | 889 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_0006897 | Biological process | endocytosis |
GO_0140367 | Biological process | antibacterial innate immune response |
GO_0044790 | Biological process | suppression of viral release by host |
GO_1905167 | Biological process | positive regulation of lysosomal protein catabolic process |
GO_0140374 | Biological process | antiviral innate immune response |
GO_0005886 | Cellular component | plasma membrane |
GO_0031410 | Cellular component | cytoplasmic vesicle |
GO_0005789 | Cellular component | endoplasmic reticulum membrane |
GO_0000139 | Cellular component | Golgi membrane |
GO_0005783 | Cellular component | endoplasmic reticulum |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0010008 | Cellular component | endosome membrane |
GO_0005765 | Cellular component | lysosomal membrane |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | MARCHF2 |
Protein name | RING-type E3 ubiquitin transferase (EC 2.3.2.27) Membrane associated ring-CH-type finger 2 E3 ubiquitin-protein ligase MARCHF2 (EC 2.3.2.27) (Membrane-associated RING finger protein 2) (Membrane-associated RING-CH protein II) (MARCH-II) (RING finger protein 172) (RING-type E3 ubiquitin transferase MARCHF2) |
Synonyms | MARCH2 RNF172 HSPC240 |
Description | FUNCTION: E3 ubiquitin-protein ligase that may mediate ubiquitination of TFRC and CD86, and promote their subsequent endocytosis and sorting to lysosomes via multivesicular bodies. E3 ubiquitin ligases accept ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfer the ubiquitin to targeted substrates . Together with GOPC/CAL mediates the ubiquitination and lysosomal degradation of CFTR . Ubiquitinates and therefore mediates the degradation of DLG1 . Regulates the intracellular trafficking and secretion of alpha1-antitrypsin/SERPINA1 and HP/haptoglobin via ubiquitination and degradation of the cargo receptor ERGIC3 . Negatively regulates the antiviral and antibacterial immune response by repression of the NF-kB and type 1 IFN signaling pathways, via MARCHF2-mediated K48-linked polyubiquitination of IKBKG/NEMO, resulting in its proteasomal degradation . May be involved in endosomal trafficking through interaction with STX6 . .; FUNCTION: (Microbial infection) Positively regulates the degradation of Vesicular stomatitis virus (VSV) G protein via the lysosomal degradation pathway . Represses HIV-1 viral production and may inhibit the translocation of HIV-1 env to the cell surface, resulting in decreased viral cell-cell transmission . . |
Accessions | M0R138 ENST00000602117.1 [Q9P0N8-1] M0R0S4 ENST00000595142.5 M0QXU4 ENST00000381035.8 [Q9P0N8-2] M0R1P2 Q9P0N8 ENST00000601283.5 ENST00000595213.1 ENST00000601724.5 ENST00000215555.7 [Q9P0N8-1] |